Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients-Reference-Cited by-全球学者库

Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients

Published:2020-01 Issue:2 Volume:21 Page:101-110
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Li Wenyan¹,Zhao Ping²,Chen Liwen¹,Lai Xiaoyin³,Shi Guohua¹,Li Longxuan³,Dong Jing¹

Affiliation:

1. Department of Pharmacy, Gongli Hospital of Pudong New Area, The Second Military Medical University, 219 Miaopu Road, Shanghai 200135, PR China

2. Department of Endocrinology, Lanshi Hospital, Qilihe District, Lanzhou 730000, PR China

3. Department of Neurology, Gongli Hospital of Pudong New Area, The Second Military Medical University, 219 Miaopu Road, Shanghai 200135, PR China

Abstract

Aim: To analyze the impact of nongenetic factors and gene polymorphisms on warfarin dose requirements in elderly Shanghai Han Chinese patients. Materials & methods: Genotypes of CYP2C9 (rs1799853 and rs1057910), FPGS (rs7856096), ApoE (rs7412 and rs429358), GGCX (rs699664 and rs12714145), EPHX1 (rs4653436, rs1877724, rs1051740 and rs1131873), NQO1 (rs1800566 and rs10517), ABCB1 (rs1045642), VKORC1 (rs9923231) and CYP4F2 (rs2108622) in 214 patients with stable warfarin dose were determined and their demographic characteristics were recorded. Results: Multiple linear regression analysis revealed that VKORC1 rs9923231, CYP2C9*3 rs1057910, ApoE rs7412, age, BMI and concomitant amiodarone could explain 37.0% of the individual variations of daily stable warfarin dose. Conclusion: VKORC1 rs9923231, CYP2C9*3 rs1057910, ApoE rs7412, age, BMI and concomitant amiodarone play an important role in stable dose variation of warfarin in elderly Shanghai Han Chinese patients, whereas ABCB1 rs1045642 is not a significant genetic factor.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2019-0139

Reference42 articles.

1. Oral Anticoagulant Therapy

2. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

3. The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score

4. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

5. The pharmacogenetics of coumarin therapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies;Clinical Pharmacokinetics;2023-06

2. Developing Chinese race-specific warfarin dose prediction algorithms;International Journal of Clinical Pharmacy;2023-03-29

3. Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis;Korean Journal of Clinical Pharmacy;2022-09-30

4. Warfarin therapy and pharmacogenetics: A narrative review of regional and Iraqi studies;Medical Journal of Babylon;2022

5. Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin;European Journal of Clinical Pharmacology;2021-10-01